🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For those who attended #ISA_2022 and/or interested The International Society Of Amyloidosis meeting 2024, Rochester, MN, conflict with current dates of June 9-13, 2024: EHA June 13-16, location tbd. Also ASCO May 31 - June 4, 2024. ESC/HFA has HF Congress end of May, dates tbd. Please answer polls below

One Week Away! 500 patients have registered. Let your patients know. Sat. 10-29-2022 LIVE WEBINAR for AL #amyloidosis patients: Mayo Amyloid BU Amyloidosis Center Morie Gertz @adsouza_md Marcus Anthony Urey MD Register Here amyloidosissupport.zoom.us/webinar/regist…

New this year at the San Diego Biomarker Symposium: Abstract and Poster Competition! Submit your abstract or case report, then enjoy the evening poster session after the conference. SDBIOMARKERSSYMPOSIUM.COM for details and full agenda, coming soon! Lori Daniels Alanmaisel

We have published a new study in REC Publications describing a new endemic ATTRv variant in the South of Ecuador 🇪🇨 See the thread by Fernando de Frutos for more details 👇🏻

Can The ISHLT & Jon Kobashigawa Cedars-Sinai achieve consensus on Ab and AMR? Spending today trying to do it! JHLT ISHLT President Lara Danziger-Isakov Kiran Khush Yas Moayedi Michelle Kittleson MD PhD Josef Stehlik Nir Uriel, MD MSc Shelley Hall Kelly Schlendorf Stanford Heart Failure, Cardiac Transplant and MCS #ISHLT2023

Big news in the #amyloidosis world with the release of top line results for the Phase 3 #acoramidis trial, ATTRIBUTE-CM. Main message: It worked! 🍾 A lot of fascinating history behind this story. What else can we learn from the data? Details to follow… (1/14)

(1/10) Today the long-awaited full results from the Phase 3 ATTRibute-CM trial were presented European Society of Cardiology #ESCCongress. We already knew the topline results from last month: Acoramidis made a (big) difference in outcomes! What more did we learn?🤔Let's dig deeper...

1/ Check out our recent publication in Journal of Cardiac Failure ! The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology - onlinejcf.com/article/S1071-…

Is apical sparing on echo sufficient for the diagnosis of cardiac amyloidosis? In this multicenter study, we identified 544 patients with CA and 200 controls (suspicion for CA but ruled out for CA), as well as 174 healthy subjects. Led by Jeremy Slivnick academic.oup.com/ehjcimaging/ad…

Congratulations to the UC San Diego Cardiology Heart Transplant Program on being named an INTERLINK ELITE program! The program was also awarded INTERLINK's 2024 Chairman's Award as the #1 performing program for heart transplant in their Programs of Excellence network!

Forgot to mention…in person or livestream available

Cardiomyopathy and Cardio-Oncology Symposium October 5, 2024 San Diego Marriott La Jolla scripps.org/sparkle-assets… Quan Bui Sarah Cuddy Kevin Alexander Ahmad Masri Dr. Purvi Parwani Rajeev Mohan Rola Khedraki, MD, FACC UC San Diego Cardiology Fellows

#AHFTC interviews underway! Train at one of the nation's highest volume centers for #HeartFailure, #HeartTransplant and #LVAD against the beautiful backdrop of San Diego. Please check out our UC San Diego Advanced Heart Failure and Transplant Cardiology Fellowship with video link

On behalf of my course co-directors Rajeev Mohan Marcus Anthony Urey MD and I, we are thrilled to be hosting our first-ever joint Scripps/UCSD Cardio-Onc and Cardiomyopathies Conference. Join us in La Jolla on Oct 5 🗓️ Register here: scripps.org/events/cardiom…

Marcus Anthony Urey MD presents the UCSD-Scripps experience in heart transplant in #cardiac #amyloidosis Marcus Anthony Urey MD Rola Khedraki, MD, FACC Kevin Alexander Eric Adler Mazen Hanna Ronald Witteles et al are pushing the envelope on this which is very much needed #CardioTwitter #amyloidosis

UCSD HF is hiring! See below to apply. apol-recruit.ucsd.edu/JPF04235

Happy to share our work focusing on a patient centered outcome for 🫀transplant patients. DCD recipients had similar 1-year days alive outside the hospital (DAOH) as DBD recipients - further supporting the use of DCD in txp 👥🫀📄 sciencedirect.com/science/articl…

Proud to share our review on transthyretin amyloid cardiomyopathy! doi.org/10.1007/s40119… We break down the current treatments, what’s in the pipeline, and what’s next. Marcus Anthony Urey MD UC San Diego Cardiology